1. Home
  2. PGNY vs URGN Comparison

PGNY vs URGN Comparison

Compare PGNY & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Progyny Inc.

PGNY

Progyny Inc.

N/A

Current Price

$36.37

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$25.77

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PGNY
URGN
Founded
2008
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.2B
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
PGNY
URGN
Price
$36.37
$25.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
7
Target Price
$36.67
★ $60.71
AVG Volume (30 Days)
995.8K
★ 1.2M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.95
N/A
Revenue
★ $1,288,661,000.00
$1,128,000.00
Revenue This Year
$6.82
$190.44
Revenue Next Year
$11.43
$69.25
P/E Ratio
$38.33
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$16.10
$16.50
52 Week High
$36.43
$50.81

Technical Indicators

Market Signals
Indicator
PGNY
URGN
Relative Strength Index (RSI) 81.77 26.38
Support Level $24.89 $22.61
Resistance Level N/A $27.76
Average True Range (ATR) 1.15 1.98
MACD 0.82 -0.62
Stochastic Oscillator 97.38 13.98

Price Performance

Historical Comparison
PGNY
URGN

About PGNY Progyny Inc.

Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: